SCHEMBL28056844

SCHEMBL28056844

O=C(OCc1ccccc1)c1ccc(C(=O)N2CCC3CC=CC=C3C2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.45
KMT2A Q03164 2/20 0.45
SLC6A2 P23975 1/20 0.45
SLC6A3 Q01959 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
BCHE P06276 6/20 0.42
RAB9A P51151 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
NPC1 O15118 1/20 0.42
TGM2 P21980 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
CYP2C19 P33261 1/20 0.41
GPR119 Q8TDV5 1/20 0.40
SLC6A7 Q99884 1/20 0.39
CHRNB2 P17787 1/20 0.39
CHRNA5 P30532 1/20 0.39
CHRNA7 P36544 1/20 0.39
CHRNA4 P43681 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28056859 0.85 FDFT1 (0.47) LMNAKMT2ATDP1RAB9ASMN1; SMN2
SCHEMBL28949869 0.81 EPHX1 (0.43) KMT2AALDH1A1HPGD
SCHEMBL28056726 0.81 NPC1 (0.41) LMNAKMT2ARAB9ANPC1MAPT
SCHEMBL28056837 0.78 ABL1 (0.40) LMNAKMT2AMAPTGPR119
SCHEMBL28056784 0.77 PARP10 (0.46) TDP1RAB9ASMN1; SMN2NPC1ALDH1A1
SCHEMBL17360240 0.74 KMT2A (0.55) LMNAKMT2ASLC6A2SLC6A3TDP1
SCHEMBL28056725 0.73 HPGD (0.60) LMNAKMT2ASLC6A2SLC6A3TDP1
SCHEMBL1028407 0.73 NPC1 (0.32) RAB9ASMN1; SMN2NPC1ALDH1A1
SCHEMBL312287 0.69 KMT2A (0.92) LMNAKMT2ASLC6A2SLC6A3TDP1
SCHEMBL10922111 0.69 QDPR (0.40) SLC6A3ALDH1A1CHRNB2CHRNA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103732589-B Can be used as the sulphonamide of the replacement of anti-apoptotic BCL inhibitor BRISTOL-MYERS SQUIBB CO. (US) 2016-03-30 CN disclosed